← All trials
NCT01955252
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2013
- Primary completion
- May 1, 2017
- Completion date
- May 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 1200
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Lihir Medical CentreLead sponsor
- University of BarcelonaOverall official - principal investigator
- World Health OrganizationCollaborator
- University of WashingtonCollaborator
- University of BarcelonaCollaborator
- Lihir Medical CentreReponsible party - principal investigator
- Government of Papua New GuineaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.